Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum.
AffiliationChristie Hospital and Holt Radium Institute, Manchester
MetadataShow full item record
AbstractTumour angiogenesis factor (TAF) has been extracted from a variety of animal and human tumours. Its ability to induce neovascularization in two bioassays, viz. rat air-sac and chick chorioallantoic membrane, is demonstrated. Similar extracts from normal tissues fail to induce angiogenesis. TAF extracts have been used to raise a xenogeneic antiserum, the specificity of which was investigated using classical immunological methods. Its ability to neutralize the biological activity of TAF using the two in vivo assays, was also demonstrated.
CitationTumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum. 1979, 23 (1):82-8 Int J Cancer
JournalInternational Journal of Cancer
- An antiserum to tumour angiogenesis factor: therapeutic approach to solid tumours.
- Authors: Battiwalla ZF, Shethna YI
- Issue date: 1989 Nov-Dec
- Quantitation of extracts containing tumour angiogenesis factor (TAF) by radioimmunometric and radioimmunoassays.
- Authors: Schor AM, Kumar S, Phillips PJ
- Issue date: 1980 Jun 15
- [Tumor necrotic factor as an inhibitor of angiogenesis].
- Authors: Sopotsinskaia EB, Lisniak IA
- Issue date: 1988 Sep-Oct
- Quantitation of angiogenesis factor in bovine retina and tumour extracts by means of radioimmunoassay.
- Authors: Shahabuddin S, Kumar S
- Issue date: 1983 May
- Identification of an inhibitor of neovascularization from cartilage.
- Authors: Moses MA, Sudhalter J, Langer R
- Issue date: 1990 Jun 15